Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial (Q45124516)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 November 2011

Language	Label	Description	Also known as
English	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial	scientific article published on 16 November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial (English)

1 reference

Europe PubMed Central

9 December 2017

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

9 December 2017

Robert F. Storey

14

1 reference

Europe PubMed Central

9 December 2017

Kenneth W Mahaffey

13

object named as

Kenneth W Mahaffey

1 reference

Europe PubMed Central

9 December 2017

16

object named as

Lars Wallentin

1 reference

Europe PubMed Central

9 December 2017

Robert A Harrington

15

object named as

Robert A Harrington

1 reference

Europe PubMed Central

9 December 2017

Jean-Pierre Bassand

2

object named as

Jean Pierre Bassand

1 reference

Europe PubMed Central

9 December 2017

3

object named as

Andrzej Budaj

1 reference

Europe PubMed Central

9 December 2017

object named as

Jan H Cornel

6

1 reference

ORCID Public Data File 2021

Richard C Becker

1

object named as

Richard C Becker

1 reference

Europe PubMed Central

9 December 2017

5

object named as

Stefan K James

1 reference

Europe PubMed Central

9 December 2017

10

object named as

Steen Husted

1 reference

Europe PubMed Central

9 December 2017

4

object named as

Daniel M Wojdyla

1 reference

Europe PubMed Central

9 December 2017

9

object named as

Jay Horrow

1 reference

Europe PubMed Central

9 December 2017

Jose Luis López-Sendón Moreno

11

object named as

Jose Lopez-Sendon

1 reference

Europe PubMed Central

9 December 2017

author name string

John French

7

1 reference

Europe PubMed Central

9 December 2017

Riitta Lassila

12

1 reference

Europe PubMed Central

9 December 2017

publication date

16 November 2011

1 reference

Europe PubMed Central

9 December 2017

European Heart Journal

1 reference

Europe PubMed Central

9 December 2017

32

1 reference

Europe PubMed Central

9 December 2017

2933-2944

1 reference

Europe PubMed Central

9 December 2017

23

1 reference

Europe PubMed Central

9 December 2017

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Mechanisms involved in adenosine triphosphate--induced platelet aggregation in whole blood.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR422

21 January 2018

Identifiers

10.1093/EURHEARTJ/EHR422

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45124516&oldid=2066474754"